A new analysis spotlights the top 20 drugs in the late-stage pipeline
The new cystic fibrosis triplet from Vertex ranks as the single most valuable late-stage therapy in the global pipeline, according to a new report from Vantage, the editorial arm of Evaluate. And they are way out ahead on the net present value scale used to rank these would-be blockbusters.
In this ranking, which you can see in full below, the Vertex triplet including VX-659 has a net present value — or NPV — of $14.4 billion as Phase III data loom, calculating costs and potential revenue.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.